Extended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants
Carolyne Onyango‐Makumbi(MUJHU Research Collaboration), Mary Glenn Fowler(Johns Hopkins University), Wafaie Fawzi(Harvard Global Health Institute), Dhayendre Moodley(Centre for the AIDS Programme of Research in South Africa), Lynda Stranix‐Chibanda(University of Zimbabwe), Anthony Mwatha(Fred Hutch Cancer Center), Karim Manji(Muhimbili University of Health and Allied Sciences), Yvonne Maldonado(Palo Alto University), Paul Richardson(University of Liverpool), Kathleen George(Family Health International 360), P. Andrew(Family Health International 360), Hoosen Coovadia(University of KwaZulu-Natal), Alicia Young(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ramadhani S. Mwiru, Arthur H. Owora(Indiana University Bloomington)
Cited by 7
Related Papers
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
Mortality risk in preterm and small-for-gestational-age infants in low-income and middle-income countries: a pooled country analysis
|The Lancet|2013|945
Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis
|BMJ|2013|885
National and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010
|The Lancet Global Health|2013|861
Non-communicable diseases in sub-Saharan Africa: what we know now
|International Journal of Epidemiology|2011|651